High hospital-related burden of treatment for multiple myeloma patients: outcomes of a feasibility study using reimbursement data from electronic health records

• Treatment burden can be measured by analyzing patients’ health care visits Electronic Health Record-reimbursement data are useful to measure treatment Queries and syntaxes require cooperation between doctors analysts differs in apparently similar hematological diseases multiple myeloma is higher than chronic lymphoid leukemia Multiple Myeloma (MM) an incurable plasma cell malignancy with intensive prolonged treatment, presumably causing a considerable of on patients. The concept defined as the work being patient its impact well-being. However, there no consistent definition method patients MM. Therefore, aim this study was determine MM compare it Chronic Lymphoid Leukaemia (CLL). We conducted retrospective analysis using reimbursement from electronic records (EHR) calculate burden. number hospital unique days. After clearance, were analysed descriptive statistics comparing different types visits, age groups, years since diagnosis, CLL Reimbursement 176 173 included analysis, which showed i) highest first year immediately after ii) small differences groups (total 0: 68.2≤65/63.8>65 21.7≤65/25.6>65 CLL), iii) rates more compared CLL. CONCLUSION: EHR provided information With improving survival, measuring clinical practice contributes decreasing patient-centred care. As other malignant diseases, new options dramatically improved survival (MM). consequence, undergo intermittent periods causes treatment. In we used retrieved Records leukaemia (CLL) (both haematological diseases), analyse undergoing results that EHR-data considerably Further development makes possible frequently monitor evaluate Eventually, may help professionals provide improve quality life reducing